Phenotypes associated with this allele

• Allele Symbol: Sirt2^tm1.1Fwa
• Allele Name: targeted mutation 1.1, Frederick W Alt
• Allele ID: MGI:4441346
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Sirt2^tm1.1Fwa/Sirt2^tm1.1Fwa	involves: 129S6/SvEvTac * C57BL/6	MGI:5503177

Genotype
MGI:5503177

hm1

• Allelic Composition: Sirt2^tm1.1Fwa/Sirt2^tm1.1Fwa
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cellular

abnormal chromosome morphology ( J:195041 )

• increased chromosome re-replication, more cells that are greater than 4n

• increased number of double strand DNA breaks, particularly in S phase cells

• increased chromosomal aberrations

abnormal cell cycle ( J:195041 )

• H2O2 treated fibroblasts are not blocked at G2/M as in controls

• increased number of cells passing through G2/M

• more fibroblasts in G1 phase and fewer in S phase

• delayed entry into S phase but faster progress through S

abnormal mitosis ( J:195041 )

• oxidative stress leads to increased mitosis

abnormal apoptosis ( J:195041 )

• cells exposed to oxidative stress progress rapidly through G1 where apoptosis occurs

neoplasm

abnormal tumor susceptibility ( J:195041 )

• increased susceptibility to skin tumors (papillomas) when treated with DMBA followed by 15 weeks of TPA application to skin

• tumors by week 8 of treatment

• 50% mortality by week 35

• no spontaneous tumors

mortality/aging

increased susceptibility to xenobiotic induced morbidity/mortality ( J:195041 )

• 50% mortality after beginning treatment with DMBA followed by 15 weeks of TPA application to skin

homeostasis/metabolism

increased susceptibility to xenobiotic induced morbidity/mortality ( J:195041 )

• 50% mortality after beginning treatment with DMBA followed by 15 weeks of TPA application to skin